North Star Asset Management Inc. reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.8% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 44,964 shares of the company’s stock after selling 828 shares during the period. North Star Asset Management Inc.’s holdings in Thermo Fisher Scientific were worth $7,152,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Thermo Fisher Scientific by 1.0% in the second quarter. Vanguard Group Inc. now owns 24,236,706 shares of the company’s stock valued at $3,581,215,000 after buying an additional 247,812 shares in the last quarter. FMR LLC increased its stake in shares of Thermo Fisher Scientific by 11.3% in the second quarter. FMR LLC now owns 8,216,645 shares of the company’s stock valued at $1,214,093,000 after buying an additional 834,858 shares during the period. BlackRock Fund Advisors increased its stake in shares of Thermo Fisher Scientific by 7.5% in the second quarter. BlackRock Fund Advisors now owns 5,834,133 shares of the company’s stock valued at $862,051,000 after buying an additional 408,363 shares during the period. Carmignac Gestion increased its stake in shares of Thermo Fisher Scientific by 23.3% in the second quarter. Carmignac Gestion now owns 4,046,550 shares of the company’s stock valued at $597,918,000 after buying an additional 763,421 shares during the period. Finally, BlackRock Group LTD increased its stake in shares of Thermo Fisher Scientific by 2.4% in the second quarter. BlackRock Group LTD now owns 3,513,706 shares of the company’s stock valued at $519,185,000 after buying an additional 80,842 shares during the period. 88.06% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) opened at 145.81 on Friday. The company has a market capitalization of $57.60 billion, a PE ratio of 29.14 and a beta of 1.24. Thermo Fisher Scientific Inc. has a 1-year low of $119.75 and a 1-year high of $160.68. The stock’s 50 day moving average is $152.92 and its 200 day moving average is $151.85.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, October 27th. The company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.97 by $0.06. The business earned $4.49 billion during the quarter, compared to the consensus estimate of $4.39 billion. Thermo Fisher Scientific had a net margin of 11.10% and a return on equity of 14.95%. Thermo Fisher Scientific’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.80 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post $8.25 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 16th. Shareholders of record on Thursday, December 15th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date is Tuesday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 12.00%.

TMO has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $178.00 target price on the stock in a research note on Monday, August 1st. Cleveland Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research note on Friday, September 9th. Mizuho set a $175.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, July 28th. Bank of America Corp. set a $180.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Friday, October 7th. Finally, Leerink Swann began coverage on shares of Thermo Fisher Scientific in a report on Thursday, November 10th. They set an “outperform” rating and a $175.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $164.37.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 30,000 shares of the business’s stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $151.17, for a total value of $4,535,100.00. Following the completion of the sale, the chief executive officer now owns 308,647 shares of the company’s stock, valued at approximately $46,658,166.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 28,797 shares of the business’s stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $151.01, for a total transaction of $4,348,634.97. Following the completion of the sale, the chief executive officer now directly owns 307,444 shares of the company’s stock, valued at approximately $46,427,118.44. The disclosure for this sale can be found here. 0.52% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

5 Day Chart for NYSE:TMO

Receive News & Stock Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related stocks with our FREE daily email newsletter.